Education
About Us
Working with TipRanks
Follow Us
PTH - ETF AI Analysis
Top Page
Invesco DWA Healthcare Momentum ETF (PTH)
Rating:60Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several of the largest positions, such as Nektar Therapeutics and Insmed, have delivered strong year-to-date gains, boosting the ETF’s overall performance.
Momentum in Health Care Sector
The ETF focuses on the health care sector, which has shown strong recent performance, aligning with its momentum-driven strategy.
Solid Short-Term Performance
The ETF has delivered strong returns over the past month and three months, indicating positive recent momentum.
Negative Factors
Sector Concentration Risk
Nearly all of the ETF’s exposure is in the health care sector, making it vulnerable to sector-specific downturns.
High Geographic Concentration
The ETF is heavily focused on U.S. companies, limiting diversification and exposure to international markets.
Above-Average Expense Ratio
The ETF charges a relatively high expense ratio compared to many other funds, which could eat into investor returns over time.
PTH vs. SPDR S&P 500 ETF (SPY)
AUM131.61M
RegionNorth America
Expense Ratio0.60%
Beta1.05
IssuerInvesco
Inception DateOct 12, 2006
Dividend YieldN/A
Asset ClassEquity
Index TrackedDorsey Wright Healthcare Tech Leaders TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume12,335
30 Day Avg. Volume12,296
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
63.58Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering56
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PTH Summary
The Invesco DWA Healthcare Momentum ETF (PTH) is an investment fund that focuses on companies in the healthcare sector, such as Medpace Holdings and Boston Scientific. It uses a strategy to invest in healthcare businesses showing strong growth trends, including biotechnology, medical devices, and pharmaceuticals. This ETF is a good option for investors who want to benefit from the innovation and growth in healthcare, driven by factors like aging populations and new technologies. However, since it focuses heavily on healthcare, its performance can be affected by changes in that sector, making it less diversified than broader market ETFs.
How much will it cost me?The Invesco DWA Healthcare Momentum ETF (Ticker: PTH) has an expense ratio of 0.6%, meaning you’ll pay $6 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on momentum-driven strategies within the healthcare sector.
What would affect this ETF?The Invesco DWA Healthcare Momentum ETF (PTH) could benefit from ongoing advancements in healthcare technology, an aging population driving demand for medical services, and increased investment in biotechnology and pharmaceuticals. However, it may face challenges from regulatory changes, pricing pressures in the healthcare industry, and potential economic downturns that could reduce consumer spending on healthcare. Its focus on U.S.-based healthcare companies and momentum-driven strategy makes it sensitive to market volatility and sector-specific trends.
PTH Top 10 Holdings
The Invesco DWA Healthcare Momentum ETF is riding the wave of innovation in the healthcare sector, with biotech names like Cidara Therapeutics and Celcuity leading the charge thanks to strong momentum and positive outlooks from recent earnings calls. However, the fund faces headwinds from lagging names like Boston Scientific, which has struggled with bearish technical signals despite solid financial performance. With nearly all holdings rooted in U.S.-based healthcare companies, the ETF is heavily concentrated in biotech and medical devices, making it a high-risk, high-reward play for investors seeking exposure to cutting-edge healthcare advancements.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Cidara Therapeutics | 6.61% | $8.67M | $6.94B | 846.26% | 60 Neutral | |
| Insmed | 4.99% | $6.55M | $42.02B | 168.32% | 54 Neutral | |
| Medpace Holdings | 4.53% | $5.94M | $15.72B | 59.87% | 79 Outperform | |
| Guardant Health | 4.47% | $5.86M | $13.21B | 188.24% | 61 Neutral | |
| Celcuity | 3.80% | $4.99M | $4.87B | 714.18% | 44 Neutral | |
| Natera | 3.79% | $4.97M | $32.08B | 33.72% | 73 Outperform | |
| Tenet Healthcare | 3.26% | $4.27M | $17.52B | 47.51% | 74 Outperform | |
| Nektar Therapeutics | 3.20% | $4.20M | $1.11B | 255.33% | 52 Neutral | |
| Boston Scientific | 3.03% | $3.98M | $137.24B | 1.91% | 79 Outperform | |
| Madrigal Pharmaceuticals | 2.92% | $3.82M | $12.98B | 80.25% | 56 Neutral |
PTH Technical Analysis
Neutral
―
Price Trends
49.10
Positive
44.54
Positive
41.36
Positive
Market Momentum
1.02
Positive
55.14
Neutral
8.86
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PTH, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 52.38, equal to the 50-day MA of 49.10, and equal to the 200-day MA of 41.36, indicating a neutral trend. The MACD of 1.02 indicates Positive momentum. The RSI at 55.14 is Neutral, neither overbought nor oversold. The STOCH value of 8.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PTH.
PTH Peer Comparison
Comparison Results
Performance Comparison
PTH
Invesco DWA Healthcare Momentum ETF
51.94
10.11
24.17%
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
PINK
Simplify Health Care ETF
―
―
―
PSCH
Invesco S&P SmallCap Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents